![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BP1002 (L-Bcl-2) is a liposomal Bcl-2 nanoparticle antisense oligonucleotide, which is under phase 1 clinical development for the treatment of refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia (CLL) patients.
Lead Product(s): BP1002,Decitabine
Therapeutic Area: Oncology Product Name: L-Bcl-2
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2024
Details:
BP1002 (L-Bcl-2) is a liposomal Bcl-2 nanoparticle antisense oligonucleotide, which is under phase 1 clinical development for the treatment of refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia (CLL) patients.
Lead Product(s): L-Bcl-2
Therapeutic Area: Oncology Product Name: BP1002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
BP1002 is a Bcl-2 inhibitor that targets the BH3 domain of the Bcl-2 protein. It is being evaluated in combination with decitabine for the treatment of refractory/relapsed acute myeloid leukemia.
Lead Product(s): BP1002,Decitabine
Therapeutic Area: Oncology Product Name: BP1002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
BP1001 (prexigebersen) is a neutral liposome incorporated with nuclease-resistant, hydrophobic P-ethoxy antisense oligodeoxynucleotides targeted to Grb2 mRNA, which is investigated for the treatment of acute myeloid leukemia.
Lead Product(s): Prexigebersen,Decitabine,Ventoclax
Therapeutic Area: Oncology Product Name: BP1001
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
BP1001-A is a modified drug product with the same drug substance as Bio-Path’s lead drug candidate, prexigebersen, but includes formulation enhancements to produce smaller drug nanoparticles, being investigated for Solid Tumors.
Lead Product(s): Prexigebersen
Therapeutic Area: Oncology Product Name: BP1001-A
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
BP1001-A is a modified drug product with the same drug substance as prexigebersen but includes formulation enhancements to produce smaller drug nanoparticles.
Lead Product(s): Liposomal Grb2 Antisense Oligonucleotide,Paclitaxel
Therapeutic Area: Oncology Product Name: BP1001-A
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
Lead Product(s): BP1002,Decitabine
Therapeutic Area: Oncology Product Name: BP1002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
BP1003 (liposomal STAT3 antisense), an RNAi nanoparticle DNA targeting STAT3, a protein associated with increased PDAC severity and poorer survival in patients with PDAC, in combination with paclitaxel or fluorouracil used as a potential treatment against cancer cells.
Lead Product(s): BP1003
Therapeutic Area: Oncology Product Name: BP1003
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
BP1003’s ability to inhibit STAT3, a protein known to be overly expressed in a number of the most difficult to treat cancers such as pancreatic cancer (PDAC), non-small cell lung cancer (NSLCL) and acute myeloid leukemia (AML), among others.
Lead Product(s): BP1003
Therapeutic Area: Oncology Product Name: BP1003
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
United States Patent and Trademark Office has granted U.S. Patent titled, "P-ethoxy nucleic acids for liposomal formulation." The new patent builds on earlier patents granted that protect the platform technology for DNAbilize®, the Company’s novel RNAi nanoparticle drugs.
Lead Product(s): Prexigebersen,Decitabine
Therapeutic Area: Oncology Product Name: BP1001
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021